- Alzheimer’s treatment Leqembi could cost Medicare up to $5 billion per year, study estimates CNBC
- Medicare, FDA urged to press ahead with new Alzheimer’s drug Leqembi The Hill
- Eisai, Biogen Alzheimer’s drug Leqembi would cost US Medicare up to $5 bln a year, study finds Reuters
- New Alzheimer’s Drug Could Cost Medicare $5B a Year Newsmax
- Eisai, Biogen Alzheimer’s drug Leqembi would cost US Medicare up to $5 bln a year, study finds ETHealthWorld
- View Full Coverage on Google News
Source link